In this work, we analyzed the predictive and prognostic capacity of several parameters related to the immune response to the tumor (i.e., NLR, PD-L1, CD8+, and FOXP3+ TILs) using a selected cohort of advanced HNSCC patients included in an organ-preservation protocol and treated with ICT. This evidence concerns the gene FOXP3 and neoplasm.